Table 1.
Patient demographics and baseline characteristics during the 12 months before the index date
| US database (N = 222,817) | UK database (N = 211,807) | ||||||
|---|---|---|---|---|---|---|---|
| Patients (classified during the pre-index period) N (%)a | Patients with ≥1 exacerbation 12-months post-index N (%)a | Patients with ≥2 asthma-exacerbations 12-months post-index N (%)a | Study population (classified during the pre-index period) N (%)a | Patients with ≥1 exacerbation 12-months post-index N (%)a | Patients with ≥2 asthma-exacerbations 12-months post-index N (%)a | ||
| Overall | 222,817 (100.0) | 27,865 (12.5) | 5,560 (2.5) | 211,807 (100.0) | 17,785 (8.4) | 3,592 (1.7) | |
| Age (years), mean (SD) | 38.0 (16.6) | 38.2 (16.4) | 38.9 (16.2) | 45.0 (20.1) | 47.5 (19.2) | 47.9 (19.1) | |
| Gender, female | 134,123 (60.2) | 17,829 (64.0) | 3,676 (66.1) | 122,577 (57.9) | 11,889 (66.9) | 2,522 (70.2) | |
| GINA Step | Step 1 | 103,415 (46.4) | 11,513 (41.3) | 2,057 (37.0) | 37,438 (17.7) | 2,019 (11.4) | 300 (8.4) |
| Step 2 | 36,616 (16.4) | 4,140 (14.9) | 780 (14.0) | 35,488 (16.8) | 2,075 (11.8) | 302 (8.4) | |
| Step 3 | 38,497 (17.3) | 4,722 (16.9) | 864 (15.5) | 78,863 (37.2) | 5,575 (31.4) | 913 (25.4) | |
| Step 4 | 36,039 (16.2) | 5,155 (18.5) | 1,109 (19.9) | 49,169 (23.2) | 4,811 (27.1) | 952 (26.5) | |
| Step 5 | 7,736 (3.5) | 2,288 (8.2) | 744 (13.4) | 10,291 (4.9) | 3,252 (18.3) | 1,117 (31.3) | |
| Not classifiable/none | 514 (0.2) | 47 (0.2) | 6 (0.1) | 558 (0.3) | 53 (0.3) | 8 (0.2) | |
| Exacerbations during the 12-month pre-index period | 0 | 180,830 (81.2) | 16,830 (60.4) | 2,498 (44.9) | 182,712 (86.3) | 10,853 (61.0) | 1,500 (41.8) |
| 1 | 36,966 (16.6) | 8,572 (30.8) | 2,010 (36.2) | 25,129 (11.9) | 5,096 (28.7) | 1,255 (34.9) | |
| 2 | 3,758 (1.7) | 1,629 (5.8) | 603 (10.8) | 2,991 (1.4) | 1,213 (6.8) | 443 (12.3) | |
| 3 | 833 (0.4) | 505 (1.8) | 232 (4.2) | 633 (0.3) | 361 (2.0) | 194 (5.4) | |
| ≥4 | 430 (0.2) | 329 (1.2) | 217 (3.9) | 342 (0.2) | 262 (1.5) | 200 (5.6) | |
| Exacerbation rate per patient year, mean (95% CI) | 0.220 (0.218, 0.222) | 0.536 (0.528, 0.545) | 0.902 (0.878, 0.928) | 0.164 (0.162, 0.165) | 0.560 (0.547, 0.573) | 1.062 (1.016, 1.110) | |
| Severe uncontrolled asthmab | Yes | 2,059 (0.9) | 1,106 (4.0) | 510 (9.2) | 2,552 (1.2) | 1,321 (7.4) | 655 (18.2) |
| No | 220,758 (99.1) | 26,759 (96.0) | 5,050 (90.8) | 209,255 (98.8) | 16,464 (92.6) | 2,937 (81.8) | |
| Severe uncontrolled eosinophilic asthmac | Yes | 114 (0.5) | 69 (2.2) | 27 (4.4) | 357 (0.7) | 217 (4.1) | 126 (10.8) |
| No | 25,131 (99.5) | 3,053 (97.8) | 580 (95.6) | 50,089 (99.3) | 5,118 (95.9) | 1,045 (89.2) | |
Further characteristics including age range, Leidy category, and proportion of days covered are listed in Additional file 1: Table S1; aproportions calculated as a percentage of the overall population in each column; bdefined as patients at GINA Step 4 or 5 with ≥2 exacerbations in the previous 12 months; cpatients with severe uncontrolled asthma criteria and blood eosinophil counts ≥300 cells/μl at baseline
CI confidence interval, GINA Global Initiative for Asthma, SD standard deviation